Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Diversifying its portfolio to include late-phase antiviral agent
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Revenue increased 11.4 per cent to Rs. 8,545 crore
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Subscribe To Our Newsletter & Stay Updated
